Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst • 16 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib
ALPINE ASCEND

Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data so far for acalabrutinib and zanubrutinib, novel BTK inhibitors for chronic lympocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Barbara Eichhorst

Final analysis of GAIA/CLL13: second-line treatment in CLL after venetoclax-based frontline 1:42
Final analysis of GAIA/CLL13: second-line treatment in CLL after venetoclax-based frontline
Barbara Eichhorst • 7 Dec 2025
Two-year follow-up results from EPCORE CLL-1: epcoritamab monotherapy in Richter’s transformation 1:29
Two-year follow-up results from EPCORE CLL-1: epcoritamab monotherapy in Richter’s transformation
Barbara Eichhorst • 7 Dec 2025
The ongoing Phase III CELESTIAL-RRCLL trial: sonrotoclax plus anti-CD20 antibody in R/R CLL/SLL 1:00
The ongoing Phase III CELESTIAL-RRCLL trial: sonrotoclax plus anti-CD20 antibody in R/R CLL/SLL
Barbara Eichhorst • 7 Dec 2025
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD 1:49
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD
Barbara Eichhorst • 14 Sep 2025

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals